A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy
Phase of Trial: Phase II
Latest Information Update: 15 May 2017
At a glance
- Drugs Brazikumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Allergan; AstraZeneca
- 05 Apr 2017 Results published in the Gastroenterology
- 28 Dec 2016 Status changed from active, no longer recruiting to completed.
- 05 Feb 2014 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.